Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation.
Apeland
Terje
T
Department of Medicine, Stavanger University Hospital, Norway. apeland@online.no
Hartmann
Anders
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D002648:Child; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005923:Glomerulosclerosis, Focal Segmental / Q000473:pathology / Q000628:therapy*; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D011183:Postoperative Complications; D012008:Recurrence; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods; D012086:Reoperation; D000069283:Rituximab; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab